By their nature, life science companies are among the more IP-dependent businesses in the corporate world. Any transactions, therefore, will require a more thorough due diligence than is the norm. Paul M Booth and Leslie Mooi outline 10 things you should know about such a company before deciding to invest in, or acquire, it
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The latest round of promotions has contributed to a 21% rise in partner headcount in the past two years, with business leaders eyeing litigation and the UPC
Newly independent King & Wood has established offices in North America, while Mallesons has entered a ‘new era’ with a 1,200-lawyer firm across Australia and Singapore